Milton C. Ault III - Jun 15, 2021 Form 4 Insider Report for Alzamend Neuro, Inc. (ALZN)

Role
10%+ Owner
Signature
/s/ Milton C. Ault, III
Stock symbol
ALZN
Transactions as of
Jun 15, 2021
Transactions value $
$676,957
Form type
4
Date filed
6/22/2021, 06:02 PM
Previous filing
Jun 14, 2021
Next filing
Jun 22, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ALZN Common Stock Purchase $17.8K +1.4K +0.03% $12.72* 5.16M Jun 15, 2021 By Digital Power Lending, LLC F1
transaction ALZN Common Stock Purchase $120K +11.1K +0.22% $10.81* 5.17M Jun 16, 2021 By Digital Power Lending, LLC F1, F2
transaction ALZN Common Stock Purchase $173K +16.5K +0.32% $10.51* 5.19M Jun 17, 2021 By Digital Power Lending, LLC F1, F3
transaction ALZN Common Stock Sale -$5.4K -500 -0.01% $10.80* 5.19M Jun 17, 2021 By Digital Power Lending, LLC F3
transaction ALZN Common Stock Purchase $153K +16.5K +0.32% $9.28* 5.2M Jun 18, 2021 By Digital Power Lending, LLC F1, F4
transaction ALZN Common Stock Sale -$4.76K -500 -0.01% $9.52* 5.2M Jun 18, 2021 By Digital Power Lending, LLC F1
transaction ALZN Common Stock Purchase $52.7K +6.5K +0.12% $8.10* 5.21M Jun 21, 2021 By Digital Power Lending, LLC F1, F5
transaction ALZN Common Stock Purchase $170K +22K +0.42% $7.73* 5.23M Jun 22, 2021 By Digital Power Lending, LLC F1, F6
holding ALZN Common Stock 15M Jun 15, 2021 By Ault Life Sciences, Inc. F7
holding ALZN Common Stock 10M Jun 15, 2021 By Ault Life Sciences Fund, LLC F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Digital Power Lending, LLC ("DPL") is a wholly-owned subsidiary of Ault Global Holdings, Inc. ("AGH"). Mr. Ault, the Executive Chairman of AGH, is deemed to have voting and investment power with respect to the securities held of record by DPL.
F2 The common stock was purchased by the reporting person in open market transactions on the transaction date, with a volume weighted average purchase price of $10.8110. The range of purchase prices on the transaction date was $10.76 to $10.87 per share. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price.
F3 The common stock was purchased by the reporting person in open market transactions on the transaction date, with a volume weighted average purchase price of $10.5115. The range of purchase prices on the transaction date was $10.37 to $10.85 per share. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price.
F4 The common stock was purchased by the reporting person in open market transactions on the transaction date, with a volume weighted average purchase price of $9.2832. The range of purchase prices on the transaction date was $9.22 to $9.51 per share. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price.
F5 The common stock was purchased by the reporting person in open market transactions on the transaction date, with a volume weighted average purchase price of $8.1027. The range of purchase prices on the transaction date was $8.04 to $8.24 per share. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price.
F6 The common stock was purchased by the reporting person in open market transactions on the transaction date, with a volume weighted average purchase price of $7.7285. The range of purchase prices on the transaction date was $7.65 to $7.74 per share. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price.
F7 Mr. Ault has sole voting and investment power with respect to the securities held of record by Ault Life Sciences, Inc.
F8 Mr. Ault has sole voting and investment power with respect to the securities held of record by Ault Life Sciences Fund, LLC.